Novartis Aktie 1200526 / CH0012005267
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
24.02.2026 13:14:43
|
Press Release: Novartis: New real--world data -2-
References
1. George DJ, et al. Real--world outcomes of [177Lu]Lu--PSMA--617 in
taxane--naïve patients with metastatic castration--resistant
prostate cancer (mCRPC): a PRECISION data platform analysis. Presented at
ASCO Genitourinary Cancers Symposium, February 26, 2026.
2. Wei XX, et al. Real--world effectiveness of systemic therapies after
[177Lu]Lu--PSMA--617 treatment in patients with metastatic
castration--resistant prostate cancer (mCRPC): a PRostatE Cancer dISease
observatION (PRECISION) data platform analysis. Presented at ASCO
Genitourinary Cancers Symposium, February 26--28, 2026.
3. National Comprehensive Cancer Network(R) (NCCN(R)) Guidelines. NCCN
Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)) - Prostate
Cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
4. George DJ, et al. Treatment utilization among patients with metastatic
hormone--sensitive prostate cancer (mHSPC) in real--world US settings: a
PRostatE Cancer dISease observatION (PRECISION) data platform analysis.
Presented at ASCO Genitourinary Cancers Symposium, February 26--28, 2026.
5. Sartor O, et al. Clinical outcomes among patients with metastatic
hormone--sensitive prostate cancer (mHSPC) in contemporary real--world US
clinical practice: a PRostatE Cancer dISease observatION (PRECISION) data
platform analysis. Presented at ASCO Genitourinary Cancers Symposium,
February 26--28, 2026.
Novartis Media Relations
E-mail: media.relations@novartis.com
Novartis Investor Relations Central
investor relations link: +41 61 324 7944
E-mail: investor.relations@novartis.com
(END) Dow Jones Newswires
February 24, 2026 07:15 ET (12:15 GMT)
Nachrichten zu Novartis AG (Spons. ADRS)
|
20.02.26 |
Novartis-Aktie kaum bewegt: Vollständiger Rückzug aus Indien besiegelt (Dow Jones) | |
|
03.02.26 |
Ausblick: Novartis gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
|
20.01.26 |
Erste Schätzungen: Novartis zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) | |
|
09.01.26 |
Novartis baut neues Radioliganden-Therapie-Werk in Florida (Dow Jones) | |
|
28.10.25 |
Ausblick: Novartis legt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
|
14.10.25 |
Erste Schätzungen: Novartis gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) |